Sugi Predict

Sugi Predict / Compounds / SCHEMBL441948

SCHEMBL441948

SCHEMBL441948

CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC(CC)C(=O)OCC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA3 P0DMS8 2/20 0.47
▸ NR1I2 O75469 2/20 0.47
▸ PTGS2 P35354 2/20 0.47
▸ PGR P06401 1/20 0.47
▸ PDE4D Q08499 1/20 0.47
▸ ALDH1A1 P00352 6/20 0.45
▸ CYP3A4 P08684 2/20 0.45
▸ ALOX15 P16050 2/20 0.45
▸ HSD17B10 Q99714 2/20 0.45
▸ TDP1 Q9NUW8 2/20 0.45
▸ TSHR P16473 1/20 0.45
▸ GRIK1 P39086 2/20 0.41
▸ GRIK2 Q13002 2/20 0.41
▸ PPARG P37231 4/20 0.39
▸ CYP19A1 P11511 4/20 0.39
▸ OXER1 Q8TDS5 3/20 0.39
▸ MAPT P10636 3/20 0.39
▸ RXRA P19793 2/20 0.39
▸ FFAR1 O14842 2/20 0.39
▸ PTGS1 P23219 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL444331 1.00 ADORA3 (0.47) ADORA3NR1I2PTGS2PGRPDE4D
SCHEMBL3205323 1.00 ADORA3 (0.47) ADORA3NR1I2PTGS2PGRPDE4D
SCHEMBL3696782 1.00 ADORA3 (0.47) ADORA3NR1I2PTGS2PGRPDE4D
SCHEMBL442023 1.00 ADORA3 (0.47) ADORA3NR1I2PTGS2PGRPDE4D
SCHEMBL3205311 1.00 ADORA3 (0.47) ADORA3NR1I2PTGS2PGRPDE4D
SCHEMBL27778350 1.00 ADORA3 (0.47) ADORA3NR1I2PTGS2PGRPDE4D
SCHEMBL13491251 0.95 ADORA3 (0.51) ADORA3NR1I2PTGS2PGRPDE4D
SCHEMBL29040694 0.94 GRIK1 (0.44) ADORA3NR1I2PTGS2PGRPDE4D
SCHEMBL3205236 0.86 ADORA3 (0.45) ADORA3NR1I2PTGS2PGRPDE4D
SCHEMBL3220534 0.86 ADORA3 (0.45) ADORA3NR1I2PTGS2PGRPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8034842-B2 Compounds PRONOVA BIOPHARMA NORGE AS (NO) 2011-10-11 — — US claimed
US-20190284129-A1 LIPID COMPOUNDS AND COMPOSITIONS AND THEIR OPTHALMIC USE BIOZEP AS (NO) 2019-09-19 — — US disclosed
WO-2017093732-A1 LIPID COMPOUNDS AND COMPOSITIONS AND THEIR OPTHALMIC USE BIOZEP AS (NO) 2017-06-08 — — WO disclosed
EP-1888727-B1 NEW DHA DERIVATIVES AND THEIR USE AS MEDICAMENTS PRONOVA BIOPHARMA NORGE AS (NO) 2015-04-15 — — EP disclosed
US-20120232143-A1 LIPID DERIVATIVES PRONOVA BIOPHARMA NORGE AS 2012-09-13 — — US disclosed
US-8178708-B2 Lipid derivatives PRONOVA BIOPHARMA NORGE AS (NO) 2012-05-15 — — US disclosed
US-20120065260-A1 NOVEL COMPOUNDS Pronova BioPhrma Norge AS 2012-03-15 — — US disclosed
US-20120065260-A1 NOVEL COMPOUNDS Pronova BioPhrma Norge AS 2012-03-15 — — US disclosed
US-8034842-B2 Compounds PRONOVA BIOPHARMA NORGE AS (NO) 2011-10-11 — — US disclosed
US-8034842-B2 Compounds PRONOVA BIOPHARMA NORGE AS (NO) 2011-10-11 — — US disclosed
US-20100240616-A1 NOVEL LIPID COMPOUNDS PRONOVA BIOPHARMA NORGE AS (NO) 2010-09-23 — — US disclosed
US-20100240616-A1 NOVEL LIPID COMPOUNDS PRONOVA BIOPHARMA NORGE AS (NO) 2010-09-23 — — US disclosed
US-7550613-B2 alpha-methoxy docosahexanoic acid ethyl ester, alpha-iodo-docosahexanoic acid ethyl ester; antidiabetic for diabetes type 2, cardiovascular disorders, obesity, amyloidosis, prophylaxis; free of 4,7,10,13,16,19-docosahexanoic acid ( DHA), alpha-methyl DHA, alpha-methyl DHA-methyl ester PRONOVA BIOPHARMA NORGE AS (NO) 2009-06-23 — — US disclosed
US-7550613-B2 alpha-methoxy docosahexanoic acid ethyl ester, alpha-iodo-docosahexanoic acid ethyl ester; antidiabetic for diabetes type 2, cardiovascular disorders, obesity, amyloidosis, prophylaxis; free of 4,7,10,13,16,19-docosahexanoic acid ( DHA), alpha-methyl DHA, alpha-methyl DHA-methyl ester PRONOVA BIOPHARMA NORGE AS (NO) 2009-06-23 — — US disclosed
US-20090105499-A1 LIPID DERIVATIVES PRONOVA BIOPHARMA NORGE AS (NO) 2009-04-23 — — US disclosed
US-20080300306-A1 Novel Compounds BRYHN MORTEN 2008-12-04 — — US disclosed
US-20080300306-A1 Novel Compounds BRYHN MORTEN 2008-12-04 — — US disclosed
WO-2007107869-A2 LIPID DERIVATIVES PRONOVA BIOPHARMA NORGE AS (NO) 2007-09-27 — — WO disclosed
US-20070088170-A1 Novel compounds PRONOVA BIOPHARMA NORGE AS (NO) 2007-04-19 — — US disclosed
US-20070088170-A1 Novel compounds PRONOVA BIOPHARMA NORGE AS (NO) 2007-04-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240616-A1 NOVEL LIPID COMPOUNDS ELOVL3, FFAR3, STARD3 ADORA3 427/4885NR1I2 276/4885PTGS2 455/4885
US-20120232143-A1 LIPID DERIVATIVES CYP4F3, STARD3, PLIN3 ADORA3 398/4885NR1I2 261/4885PTGS2 2830/4885
US-20190284129-A1 LIPID COMPOUNDS AND COMPOSITIONS AND THEIR OPTHALMIC USE APOB, ALOX12, NR1H2 ADORA3 2246/4885NR1I2 135/4885PTGS2 313/4885
US-20070088170-A1 Novel compounds FFAR2, GPR119, ALOX12 ADORA3 756/4885NR1I2 273/4885PTGS2 334/4885
US-20080300306-A1 Novel Compounds GPR119, FFAR2, ALOX12 ADORA3 730/4885NR1I2 288/4885PTGS2 371/4885
US-20120065260-A1 NOVEL COMPOUNDS FFAR2, GPR119, ALOX12 ADORA3 756/4885NR1I2 273/4885PTGS2 334/4885
US-20090105499-A1 LIPID DERIVATIVES PLIN3, STARD3, CYP4F3 ADORA3 451/4885NR1I2 194/4885PTGS2 2091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.